• Xuemeng Chen, Ye Zhao, Ran Zhang, Yan Zhao, and Liheng Dai.
• Department of Public Health, International College, Krirk University, Bangkok, Thailand.
• Medicine (Baltimore). 2023 Oct 20; 102 (42): e35717e35717.

BackgroundTo systematically evaluate the effects of vitamin D supplementation in patients with nonalcoholic fatty liver disease (NAFLD).MethodsNational Library of Medicine, Cochrane Library, Elsevier, China National Knowledge Infrastructure, Web of Science, WANFANG databases, and Google Scholar were retrieved to collect relevant randomized controlled trials, which are published from the earliest records the time the database was created to April 2023. Meta-analysis was conducted by using Review Manager 5.4 software after evaluating in terms of inclusion and exclusion criteria. The outcome indicators include 25-hydroxyvitamin D [25(OH)D] levels, insulin resistance index (homeostasis model assessment of insulin resistance), fasting blood glucose, and fasting insulin levels (FINS).ResultsEight randomized controlled trials with a total of 657 patients are included. Vitamin D supplementation increased 25(OH)D levels significantly (mean difference [MD] = 2.01, 95% confidence intervals [CI]: 0.94 to 3.08, P < .05) and vitamin D supplementation had a significant effect on insulin resistance index (MD = -0.54, 95% CI: -1.28 to 0.20, P = .16), fasting glucose (MD = -0.59, 95% CI: -1.50 to 0.32, P = .20), and FINS levels (MD = -0.30, 95% CI: -0.77 to 0.17, P = .21) had no significant effect.ConclusionVitamin D supplementation improves 25(OH)D levels in patients with nonalcoholic fatty liver disease, but there is no effect on homeostasis model assessment of insulin resistance, fasting blood glucose, or FINS.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

11 keywords...

hide…